Short answer
Danaher Corporation (DHR) filed its Q2 2026 10-Q quarterly report on Jul 21, 2026 for the quarter ended Jun 26, 2026. Quarterly revenue was $6.3B (up 5.5% year over year) with net income of $870M.
Q2 2026 key financials · XBRL
- Revenue
- $6.3B
- +5.5% YoY · +5.3% QoQ
- Net income
- $870M
- +56.8% YoY · −15.5% QoQ
- Operating margin
- 18.0%
- Gross margin
- 57.6%
- EPS (diluted)
- $1.23
- +57.7% YoY · −15.2% QoQ
Source: XBRL data from the Danaher Corporation (DHR) Q2 2026 10-Q on SEC EDGAR. USD.
Danaher Corporation Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue up 5.5% YoY; core sales up 3.0%, or 4.5% excluding respiratory testing
- Operating margin 18.0% vs 12.8% YoY, up 520 basis points
- Life Sciences strongest core-sales contributor; Diagnostics benefited from Masimo acquisition
- Masimo acquired for approximately $9.8B, financed with cash and new debt
- Outlook headwinds: tariff uncertainty, Middle East logistics costs, currency exposure and potential demand pressures
Risk Factors
- New risk: Middle East military conflict during 2026, disrupting energy supplies and supply chains
- Regulatory risk: Sanctions and embargoes from military conflicts threatening business operations
- Market risk: Capital-markets volatility and increased cyber-attacks from escalating hostilities
- Cost risk: Higher energy and supply costs creating inflationary pressures
- Financial risk: Capital-markets dislocation potentially adversely affecting financial statements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Danaher Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.